Cargando…
P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431020/ http://dx.doi.org/10.1097/01.HS9.0000971228.21453.6e |
| _version_ | 1785091099745845248 |
|---|---|
| author | Taszner, Michał Luminari, Stefano Cho, Seok-Goo Novelli, Silvana Le Gouill, Steven Poon, Michelle Villasboas, Jose Champion, Rebecca Bachy, Emmanuel Guidez, Stephanie Alonso Alonso, Aránzazu Jagadeesh, Deepa Merli, Michele Tucker, David Cai, Jingxian Leite de Oliveira, Carolina Zhu, Min Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Min Kim, Tae |
| author_facet | Taszner, Michał Luminari, Stefano Cho, Seok-Goo Novelli, Silvana Le Gouill, Steven Poon, Michelle Villasboas, Jose Champion, Rebecca Bachy, Emmanuel Guidez, Stephanie Alonso Alonso, Aránzazu Jagadeesh, Deepa Merli, Michele Tucker, David Cai, Jingxian Leite de Oliveira, Carolina Zhu, Min Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Min Kim, Tae |
| author_sort | Taszner, Michał |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431020 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104310202023-08-17 P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 Taszner, Michał Luminari, Stefano Cho, Seok-Goo Novelli, Silvana Le Gouill, Steven Poon, Michelle Villasboas, Jose Champion, Rebecca Bachy, Emmanuel Guidez, Stephanie Alonso Alonso, Aránzazu Jagadeesh, Deepa Merli, Michele Tucker, David Cai, Jingxian Leite de Oliveira, Carolina Zhu, Min Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Min Kim, Tae Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431020/ http://dx.doi.org/10.1097/01.HS9.0000971228.21453.6e Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Taszner, Michał Luminari, Stefano Cho, Seok-Goo Novelli, Silvana Le Gouill, Steven Poon, Michelle Villasboas, Jose Champion, Rebecca Bachy, Emmanuel Guidez, Stephanie Alonso Alonso, Aránzazu Jagadeesh, Deepa Merli, Michele Tucker, David Cai, Jingxian Leite de Oliveira, Carolina Zhu, Min Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Min Kim, Tae P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 |
| title | P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 |
| title_full | P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 |
| title_fullStr | P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 |
| title_full_unstemmed | P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 |
| title_short | P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 |
| title_sort | p1083: odronextamab in patients with relapsed/refractory follicular lymphoma grade 1–3a: results from a prespecified analysis of the pivotal phase 2 study elm-2 |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431020/ http://dx.doi.org/10.1097/01.HS9.0000971228.21453.6e |
| work_keys_str_mv | AT tasznermichał p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT luminaristefano p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT choseokgoo p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT novellisilvana p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT legouillsteven p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT poonmichelle p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT villasboasjose p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT championrebecca p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT bachyemmanuel p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT guidezstephanie p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT alonsoalonsoaranzazu p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT jagadeeshdeepa p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT merlimichele p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT tuckerdavid p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT caijingxian p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT leitedeoliveiracarolina p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT zhumin p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT chaudhryaafia p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT mohamedhesham p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT ambatisrikanth p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 AT minkimtae p1083odronextamabinpatientswithrelapsedrefractoryfollicularlymphomagrade13aresultsfromaprespecifiedanalysisofthepivotalphase2studyelm2 |